Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Change from baseline in rectal functions
Assessment of rectal toxicity according to the NCI-CTCAE v4.0 scale. Acute toxicities are defined as all toxicities occurring within 6 months after the start of radiotherapy, late toxicities are those that occur beyond this period.
Every 3 months after boost irradiation during 1 year and then every 6 months during 2 years
Eric LARTIGAU, MD, PhD
Centre Oscar Lambret
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)